EUVIMEDEUVIMED entdecken
Crossref

Two new options for NPM1 ‐mutated relapsed, refractory acute myeloid leukemia

Leah Lawrence

Cancer · 01.03.2026 · 132 (5)

DOI: 10.1002/cncr.70275 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 04.03.2026. Verfasst von Leah Lawrence. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, the FDA recently approved two menin inhibitors for the treatment of relapsed or refractory acute myeloid leukemia with NPM1 mutations: revumenib and ziftomenib. In addition, the FDA also approved the subcutaneous injection of anti‐CD38 monoclonal antibody daratumumab and hyaluronidase‐fihj for patients with high‐risk smoldering multiple myeloma, and oral TKI sevabertinib is approved for advanced HER2 ‐mutant NSCLC.

Zitieren

APA

Lawrence, L. (2026). Two new options for NPM1 ‐mutated relapsed, refractory acute myeloid leukemia. Cancer, 132(5). https://doi.org/10.1002/cncr.70275

Vancouver

Lawrence L. Two new options for NPM1 ‐mutated relapsed, refractory acute myeloid leukemia. Cancer. 2026;132(5). doi:10.1002/cncr.70275

BibTeX
@article{Lawrence2026,
  author = {Lawrence, Leah},
  title = {Two new options for NPM1 ‐mutated relapsed, refractory acute myeloid leukemia},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {5},
  doi = {10.1002/cncr.70275}
}
Kostenlos starten →